Thioredoxin reductase 1, cytoplasmic · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Thioredoxin reductase 1, cytoplasmic shows approved-linked disease relevance led by acute promyelocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q16881. Start with acute promyelocytic leukemia, then reuse UniProt Q16881 as the stable protein anchor across project notes and exports.
Start with acute promyelocytic leukemia, then reuse UniProt Q16881 as the stable protein anchor across project notes and exports.
Thioredoxin reductase 1, cytoplasmic shows approved-linked disease relevance led by acute promyelocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with acute promyelocytic leukemia because it currently carries approved-linked support. Linked drugs include ARSENIC TRIOXIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyThioredoxin reductase 1, cytoplasmic
Review this target as Thioredoxin reductase 1, cytoplasmic, mapped to UniProt Q16881. Sequence length is 649 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Thioredoxin reductase 1, cytoplasmic as ChEMBL target CHEMBL1927, mapped to UniProt Q16881. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Thioredoxin reductase 1, cytoplasmic is the right protein anchor across sources, using UniProt Q16881 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute promyelocytic leukemia is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Thioredoxin reductase 1, cytoplasmic |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q16881 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Thioredoxin reductase 1, cytoplasmic |
| UniProt Accession | Q16881 |
| Component Type | Protein |
| Sequence Length | 649 aa |
Thioredoxin reductase 1, cytoplasmic
Review this target as Thioredoxin reductase 1, cytoplasmic, mapped to UniProt Q16881. Sequence length is 649 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Thioredoxin reductase 1, cytoplasmic shows approved-linked disease relevance led by acute promyelocytic leukemia. 5 more disease programs remain visible in the same review block.
Start review with acute promyelocytic leukemia because it currently carries approved-linked support. Linked drugs include ARSENIC TRIOXIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5858773 | 9.07 | IC50 | 0.854 | Preclinical |
| CHEMBL6007625 | 8.99 | IC50 | 1.03 | Preclinical |
| CHEMBL5891038 | 8.82 | IC50 | 1.52 | Preclinical |
| CHEMBL5749180 | 8.5 | IC50 | 3.16 | Preclinical |
| CHEMBL5965472 | 8.4 | IC50 | 3.99 | Preclinical |
| CHEMBL5863993 | 8.36 | IC50 | 4.35 | Preclinical |
| CHEMBL5900218 | 8.3 | IC50 | 5.05 | Preclinical |
| CHEMBL5917158 | 8.26 | IC50 | 5.5 | Preclinical |
| CHEMBL5758824 | 8.17 | IC50 | 6.78 | Preclinical |
| CHEMBL5965930 | 8.16 | IC50 | 6.9 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 20 | 18 | 5.2 |
| single protein format | 13 | 64 | 7.0 |
| assay format | 3 | 0 | — |